WeWork (NYSE: WE) shares rocket a staggering 155% amongst substantial doubt‘ it can stay in business. In a situation where there have been no press releases or SEC filings regarding the company, the market’s response is undeniably intriguing, especially considering the company’s apparent proximity to bankruptcy. However, upon conducting more thorough research, we’ve come across potential indicators that shed light on today’s developments.
Before we continue, let’s take a look at the company as a whole and significant events that have transpired in recent years.
Subscribe to Microcapdaily.com Right Now by entering your Email in the box below.
Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!
Initially appearing to be an ingenious transformation toward a $47 billion IPO, bolstered by major investment banks, SoftBank’s illusionist moves, WeWork has gone from a 47B evaluation, to a mere 146M at time of writing. One of the companies largest investors, SoftBank, released a recent SEC filing revealing a staggering $18.6 billion cumulative loss on its investment in WeWork, portraying SoftBank’s once seemingly magical maneuver as a misstep in strategy.
It is important to note that a documentary on the company came out in 2021, and points to it being one of the largest scams in our era, we’ve provided a link to the trailer below:
The scrutiny of diligent journalists at WSJ and FT, armed with pertinent inquiries, revealed nothing but Neumann’s skillful yet questionable financial games and a haze of exuberant anticipation. As more people examined this potentially historic swindle, what nearly evolved into the grandest scam of our era suddenly collapsed under its own weight, akin to a slight breeze dismantling a house of cards carefully built by Neumann, who’s also commonly referred to as, “The Grifter”.
The WeWork documentary casts a spotlight on the twisted values entrenched in our society. Alan Neumann, walks away from the WeWork deception with nearly a billion dollars, a far cry from WeWork employees left with nothing but empty hands. Ponder the near-miss scenario where this colossal fraud nearly victimized a majority of investors and institutions, leaving them holding worthless assets. Reflect on the candid criticism expressed by Charlie Munger toward SPACs, yet WeWork found its way to the public domain through a SPAC at a mere $9 billion valuation.
Presently, its shares are trading between 15 and 20 cents. But regardless of the negative light shone on the company by multiple articles and a documentary, it appears retail traders have a different trajectory in mind.
Thoughts from Retail Investors
WeWork stock, $WE, is up 116% a day after the company said they have "substantial doubt" about their ability to say in business.
As affirmed by numerous retail investors, the answer is yes. The post above proceeded to garner a staggering amount of attention on the platform Reddit, which commonly holds separate trading groups like /rwallstreetbets for retail traders to actively discuss daily investments.
The user responsible for the post dedicated themselves to a comprehensive due diligence on the company. However, it’s noteworthy that a majority of individuals within the thread have opted to disregard this diligent investigation in its entirety. Instead, they’ve embarked on purchasing stocks driven by the rationale that “this trade is so dumb as it can get, so it will go to the moon of course” said by “beaten_by_monkeys”
Additionally, a noticeable trend involves numerous traders on another platform,Twitter, where many are becoming attracted to the inherent volatility of the company. These traders are observing trading patterns that bear resemblance to previous memestocks, such as GameStop (NYSE: GME).
Maintaining a vigilant watch over WeWork (NYSE: WE) in the coming weeks could prove prudent, given its ongoing susceptibility to volatile trading. Retail investors have shown a growing interest in the stock, evident from multiple posts amassing tens of thousands of impressions within a mere 24-hour span.
However, it’s imperative to exercise caution, trade with awareness of associated risks, and conduct thorough individual research. It’s worth noting that this stock lacks substantial fundamentals and teeters on the brink of bankruptcy. Hence, consider this a high-stakes “Yolo” scenario, capable of either propelling your investment or causing its complete downfall.
We will update you on WE when more details emerge, subscribe to Microcapdaily to follow along!
Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!
Disclosure: We have not been compensated for this article/video. MicroCap Daily is not an investment advisor; this article/video does not provide investment advice. Always do your research, make your own investment decisions, or consult with your nearest financial advisor. This article/video is not a solicitation or recommendation to buy, sell, or hold securities. This article/video is our opinion, is meant for informational and educational purposes only, and does not provide investment advice. Past performance is not indicative of future performance.
Shares of T2 Biosystems (NASDAQ:TTOO) are soaring up over 20% today on the heels of receiving a 510(k) clearance for its T2Biothreat from the FDA. This unique test directly detects six biothreat pathogens from a blood sample.
Spotting Biothreats Faster:
T2Biothreat Panel is a game-changer, being the first and only FDA-approved product that can spot these critical biothreat pathogens simultaneously. T2 Biosystems proudly stands as the first U.S. company to achieve this milestone, reshaping the field of biothreat detection.
Big Investor Sells:
Interestingly while celebrating this achievement, a significant investor, CR Group (CRG), decided to sell off a substantial chunk of shares. This sell-off, totaling 24.81 million shares, took place between Sept. 20 and Sept. 26. The timing of this sell-off alongside the FDA clearance raises some eyebrows.
Subscribe to Microcapdaily.com Right Now by entering your Email in the box below.
Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!
New CDC Guidelines:
Regardless of CR Group selling, there still appears to be a massive opportunity according to many retail investors. Following new CDC guidelines, the U.S. government now mandates that all hospitals in the country must adopt rapid testing protocols to combat the sepsis pandemic by 2026, or risk losing Medicare funding.
T2 Biosystems stands as the exclusive FDA-cleared product capable of achieving 100% accurate sepsis detection within 3 to 5 hours. Anticipating widespread adoption of T2 instruments in hospitals, the CEO foresees significant revenue generation, potentially reaching $1.3 billion annually, given the mandate.
This development drastically alters the landscape, potentially influencing the stock’s trajectory positively. With the ongoing surge in manufacturing hires and likely acceleration in orders, coupled with potential government contracts or international sales, many beleive T2 Biosystems presents an undervalued opportunity for investors.
What Borrowing Costs Tell Us:
Another interesting indicator to look at is the cost to borrow (CTB) fee. In terms of TTOO’s case, the stock has seen a massive surge in CTB fees, indicating a high demand from short sellers. When compared to the average CTB fee for other stocks, it’s pretty drastic. While this is typically not a very positive sign, retail investors seem to be buzzing with interest, given there also could be a potential short squeeze if enough buying comes in to trap the shorts.
Better News for Patients:
But let’s not forget the real impact and that’s what TTOO can do for patients. @ChengKeki a user from Twitter also shared an article about Butler Memorial Hospital and their approach to Sepsis. The hospital came up with a 2 step approach to expedite patient care. They’re utilizing the Beckman Coulter automation line to identify changes in a person’s blood cells that might indicate the development of sepsis. Which apparently has only been used in Europe and they’re the first in the US with the technology. Then shortly after, they use T2 Biosystems panels that as you know, quicken the process from 36 hours, to just 3-5 hours.
Catching sepsis quickly is crucial because it’s a life-threatening condition that rapidly progresses throughout your body and can lead to death if not promptly diagnosed and treated. Sepsis occurs when the body responds improperly to an infection, causing widespread inflammation and potentially damages multiple organ systems. Early detection allows for immediate medical intervention.
Conclusion:
T2 Biosystems is hitting major milestones, not only in the market but in improving critical healthcare processes. The company is also a major hit with retail investors and continues to trade an astronomical amount of shares daily, the current average is ~115M shares. The FDA approval and its implications, along with the positive shift in sepsis diagnosis, showcase T2 Biosystems’ growing role in healthcare. Keep an eye on how this progresses—it’s exciting for both investors and patients alike.
We will update you on TTOO when more details emerge, subscribe to Microcapdaily to follow along!
Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!
Organogenesis Holdings (NASDAQ: ORGO), a top regenerative medicine company dedicated to advanced wound care, surgical, and sports medicine solutions, gains over 30% during intraday trading and after hours combined after their latest release. According to the release, three Medicare Administrative Contractors (MACs) decided to withdraw certain coverage rules that were meant to start on October 1. These rules related to products for treating diabetic foot ulcers (DFU) and venous leg ulcers (VLU).
More Background:
Organogenesis serves a range of clients, from hospitals and wound care centers to doctors’ offices. The MACs’ initial rules, set on August 9, caused concern. They specified that covered products must be particular types of skin substitutes. Unfortunately, this excluded five products from Organogenesis, impacting their financial outlook.
Fast forward, the MACs pulled back these rules just in time, preventing potential harm to Organogenesis. Even before these rules, the company was facing challenges. In the second quarter, revenue was slightly down compared to the same period last year. Despite this, the company is doing better than the previous year in a six-month comparison.
Subscribe to Microcapdaily.com Right Now by entering your Email in the box below.
Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!
Gary S. Gillheeney, Sr., the head of Organogenesis, expressed deep gratitude for the MACs and the Centers for Medicare & Medicaid Services (CMS). He praised their thoughtful consideration of stakeholder concerns and putting patients first. This decision will positively affect the lives of many.
He also thanked the stakeholders, including doctors, patient advocacy groups, and various associations. Their unified support played a vital role in challenging these rules, considering the potential harm they could cause patients. Their advocacy shed light on the possible negative health outcomes and treatment disparities, especially for those with higher rates of diabetes and related conditions. Their collective efforts made a significant difference.
We will update you on ORGO when more details emerge, subscribe to Microcapdaily to follow along!
Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!
Disclosure: We have not been compensated for this article/video. MicroCap Daily is not an investment advisor; this article/video does not provide investment advice. Always do your research, make your own investment decisions, or consult with your nearest financial advisor. This article/video is not a solicitation or recommendation to buy, sell, or hold securities. This article/video is our opinion, is meant for informational and educational purposes only, and does not provide investment advice. Past performance is not indicative of future performance.
Femasys Inc. (NASDAQ: FEMY) hit a massive milestone and saw shares soar by a whopping 346%. The reason? The United States Food and Drug Administration (FDA) has given the thumbs up for the commercialization of FemaSeed, a game-changing option for artificial insemination aiming to boost the natural fertilization process.
FemaSeed:
It’s a breakthrough treatment for infertility, designed to carry sperm right to where conception happens in a woman’s fallopian tube. This breakthrough could change the game in infertility treatments by offering a less invasive option compared to heavy hitters like in vitro fertilization (IVF) or intracytoplasmic sperm injection (ICSI), potentially reducing the risk of complications during the procedure.
Kathy Lee-Sepsick, Femasys’ founder and CEO, is beyond excited about the FDA’s green light for FemaSeed. She highlights how this could be a game-changer in providing infertility treatments that are less of a burden. The FDA clearance is a testament to successful teamwork with the FDA and a major step forward in making this new technology available to those struggling with infertility.
Subscribe to Microcapdaily.com Right Now by entering your Email in the box below.
Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!
The rising numbers of infertility cases in the United States (about 10 million women, as per the Center for Disease Control) show how crucial it is to have accessible and effective infertility treatments. FemaSeed is ready to meet this need by offering an affordable and efficient option for those dealing with infertility.
Here’s an interesting tidbit: FemaSeed works in harmony with FemVue, Femasys’ FDA-cleared diagnostic device. FemVue lets doctors perform an in-office ultrasound assessment of the fallopian tubes, helping diagnose infertility even before going for FemaSeed.
But wait, there’s more! Femasys isn’t just about FemaSeed. They’re also charging ahead with FemBloc, their lead candidate for permanent birth control in late-stage clinical development. Their commitment is to provide accessible solutions for women’s health, covering unmet needs with a range of innovative in-office products.
In a nutshell, Femasys is all about empowering women and couples facing fertility challenges. Their aim? To provide cost-effective and less invasive infertility treatments, backed by innovative diagnostic solutions. With this FDA clearance for FemaSeed, Femasys is a step closer to achieving this mission and leaving a lasting impact in the realm of women’s healthcare.
We will update you on FEMY when more details emerge, subscribe to Microcapdaily to follow along!
Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!
Disclosure: We have not been compensated for this article/video. MicroCap Daily is not an investment advisor; this article/video does not provide investment advice. Always do your research, make your own investment decisions, or consult with your nearest financial advisor. This article/video is not a solicitation or recommendation to buy, sell, or hold securities. This article/video is our opinion, is meant for informational and educational purposes only, and does not provide investment advice. Past performance is not indicative of future performance.